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IMPORTANCE Schizophrenia is a clinically heterogeneous disorder. It is currently unclear how
variability in symptom dimensions and cognitive ability is associated with genetic liability for
schizophrenia.
OBJECTIVE To determine whether phenotypic dimensions within schizophrenia are
associated with genetic liability to schizophrenia, other neuropsychiatric disorders, and
intelligence.
DESIGN, SETTING, AND PARTICIPANTS In a genetic association study, 3 cross-sectional samples
of 1220 individuals with a diagnosis of schizophrenia were recruited from community,
inpatient, and voluntary sector mental health services across the UK. Confirmatory factor
analysis was used to create phenotypic dimensions from lifetime ratings of the Scale for the
Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms, and the
MATRICS Consensus Cognitive Battery. Analyses of polygenic risk scores (PRSs) were used to
assess whether genetic liability to schizophrenia, other neuropsychiatric disorders, and
intelligence were associated with these phenotypic dimensions. Data collection for the
cross-sectional studies occurred between 1993 and 2016. Data analysis for this study
occurred between January 2019 and March 2021.
MAIN OUTCOMES AND MEASURES Outcome measures included phenotypic dimensions
defined from confirmatory factor analysis relating to positive symptoms, negative symptoms
of diminished expressivity, negative symptoms of motivation and pleasure, disorganized
symptoms, and current cognitive ability. Exposure measures included PRSs for schizophrenia,
bipolar disorder, major depression, attention-deficit/hyperactivity disorder, autism spectrum
disorder, and intelligence.
RESULTS Of the 1220 study participants, 817 were men (67.0%). Participants’ mean (SD) age
at interview was 43.10 (12.74) years. Schizophrenia PRS was associated with increased
disorganized symptom dimension scores in both a 5-factor model (β = 0.14; 95% CI,
0.07-0.22; P = 2.80 × 10−4) and a 3-factor model across all samples (β = 0.10; 95% CI,
0.05-0.15; P = 2.80 × 10−4). Current cognitive ability was associated with genetic liability to
schizophrenia (β = −0.11; 95% CI, −0.19 to −0.04; P = 1.63 × 10−3) and intelligence (β = 0.23;
95% CI, 0.16-0.30; P = 1.52 × 10−10). After controlling for estimated premorbid IQ, current
cognitive performance was associated with schizophrenia PRS (β = −0.08; 95% CI, −0.14 to
−0.02; P = 8.50 × 10−3) but not intelligence PRS.
CONCLUSIONS AND RELEVANCE The findings of this study suggest that genetic liability for
schizophrenia is associated with higher disorganized dimension scores but not other
symptom dimensions. Cognitive performance in schizophrenia appears to reflect distinct
contributions from genetic liabilities to both intelligence and schizophrenia.
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T he clinical heterogeneity of schizophrenia andrelated psychotic disorders has long been recognized.Factor analyses of symptoms related to schizo-
phrenia have consistently resulted in positive, negative,
and disorganized dimensions.1,2 Studies have also identified
dimensions relating to cognitive ability, which, although
not considered a core diagnostic feature, has been con-
sistently shown to be impaired in schizophrenia.3,4 A
better understanding of the different factors underlying
these symptom dimensions could contribute to the devel-
opment of novel treatments for schizophrenia; currently
available treatments predominantly affect only positive
symptoms.
he genetic contribution to clinical variation between
patients across symptom dimensions has been of interest
for some time. Familial aggregation for a disorganized
symptom dimension has been found in studies of affected
sib-pairs5,6 and multigeneration families,7 although twin-
based analysis has indicated that this aggregation is
substantially a genetic effect (heritability; h2 = 84%).1 The
disorganized dimension also demonstrates patterns of
familial aggregation consistent with it being a marker of
genetic loading for psychotic disorders.2 Evidence for famil-
ial aggregation of the positive and negative dimensions is
less consistent, but the negative dimension has also been
associated with genetic loading for psychotic disorders.8
Recent genomic studies have used polygenic risk scores
(PRSs) to assess the association between schizophrenia
genetic liability and phenotypic dimensions. The schizo-
phrenia PRS has been reported to be associated with a com-
bined disorganized/negative dimension9,10 and with nega-
tive symptoms.4,11,12 However, many of these studies have
not assessed disorganized symptoms or are based on a
dimensional structure that combines disorganized symp-
toms with either negative symptoms9,10,13 or cognition.3
Furthermore, there is emerging evidence that indicates the
structure of negative symptoms may not be unidimensional
and that at least 2 substructures can be reliably identified:
diminished expressivity and diminished motivation and
pleasure.14,15 The association of genetic liability with other
psychiatric disorders on symptom dimensions in schizo-
phrenia is unclear.
Cognitive ability in the general population is a highly
heritable trait.16 However, studies investigating the genetic
source of the cognitive deficits observed in individuals with
schizophrenia and the association with schizophrenia
genetic liability have reported inconsistent findings.17-19
In this genetic association study, we aimed to examine
which phenotypic dimensions of schizophrenia are associ-
ated with genetic liability to schizophrenia as indexed by
PRSs. We addressed gaps in previous studies by defining
each of the commonly found symptom dimensions and
cognitive ability as distinct phenotypic dimensions and con-
ducted a meta-analysis across 3 samples that used a com-
mon approach to phenotypic assessment. We also investi-
gated the association between phenotypic dimensions and




This genetic association study included a total of 1220 indi-
viduals with schizophrenia. Participants came from 3 schizo-
phrenia sample collections, all previously reported: the Car-
diffCOGS (n = 697),20 Cardiff F-series (n = 383),21 and Cardiff
Affected-Sib (n = 140) samples5 (eTable 1 in the Supplement
provides demographic characteristics). All studies had the
relevant UK National Health Service ethical approval, and
written informed consent was obtained for all study partici-
pants. All participants underwent a comprehensive clinical
research interview based on the Schedules for Clinical
Assessment in Neuropsychiatry22 and met Diagnostic and
Statistical Manual of Mental Disorders (Fourth Edition)23 or
International Statistical Classification of Diseases and Related
Health Problems, 10th Revision24 criteria for a diagnosis of
schizophrenia or schizoaffective disorder, depressed type.
Recruitment to each study was from community, inpatient,
and voluntary sector mental health services across the UK.
The Cardiff Affected-Sib sample included a single affected
individual from families with 2 or more siblings diagnosed
with schizophrenia. The study was conducted at the MRC
Centre for Neuropsychiatric Genetics and Genomics at Car-
diff University, UK. Data collection for the cross-sectional
studies occurred between 1993 and 2016. Data analysis for
this study occurred between January 2019 and March 2021.
This study followed the Strengthening the Reporting of
Genetic Association Studies (STREGA) reporting guideline.
Phenotype Measures
In each of the 3 samples, the Scale for the Assessment of Posi-
tive Symptoms25 and the Scale for the Assessment of Nega-
tive Symptoms26 were scored on a lifetime worst basis using
information from the Schedules for Clinical Assessment in Neu-
ropsychiatry interview and lifetime psychiatric clinical case
notes. Measures of cognition were available in the Cardif-
fCOGS sample only: we used the MATRICS Consensus Cog-
nitive Battery domain and composite scores27 as a measure of
Key Points
Question Are phenotypic dimensions in schizophrenia associated
with genetic liability to schizophrenia, other neuropsychiatric
disorders, and intelligence?
Findings In this cross-sectional genetic association study of 1220
individuals with schizophrenia, analyses indicated that higher
levels of disorganized symptoms, but not other symptom
dimensions, and lower levels of current cognitive ability were
significantly associated with schizophrenia polygenic risk scores.
Current cognitive ability was also associated with intelligence
polygenic risk scores.
Meaning The findings of this study suggest that variation in
disorganized symptoms and cognitive ability in schizophrenia are
markers of schizophrenia common genetic liability; cognitive
performance in schizophrenia may reflect distinct contributions
from genetic liabilities to both intelligence and schizophrenia.
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current cognitive ability and the National Adult Reading Test28
as a measure of estimated premorbid IQ. eTable 2 in the
Supplement details the phenotype measures used.
Trained psychiatrists or psychology graduates com-
pleted the clinical ratings and cognitive assessments under the
supervision of study principal investigators (consultant psy-
chiatrists) (A.G.C., S.Z., M.J.O., M.C.O., and J.T.R.W.), and regu-
lar interrater reliability was measured. The Scale for the As-
sessment of Positive Symptoms and Scale for the Assessment
of Negative Symptoms ratings had good interrater reliability
in each sample, with κ values ranging from 0.72 to 0.95. In-
terrater reliability for research diagnosis was described in a pre-
vious publication.29
Genetic Data
All samples were genotyped on the Illumina HumanOmniEx-
press (version 8 or 12). Details relating the quality control and
imputation of genetic data are provided in eAppendix 1 in the
Supplement. Genetic principal components representing ances-
try were derived using PLINK, version 2.030 using single-
nucleotide variants with low levels of linkage disequilibrium (r2
<0.2 and 500-kilobyte window; criteria used by the Psychiatric
Genomics Consortium31). All genetic analyses were restricted to
individuals of European ancestry as assessed by principal com-
ponents. Our sample contained too few participants of non-
European ancestry to analyze. First-degree relatives (π >0.4) both
within and between samples were identified, and 1 member of
each related pair was removed, preferentially retaining samples
that had more complete phenotype data and otherwise re-
moved at random.
Polygenic Risk Scores
Polygenic risk scores were calculated using PRSice32 follow-
ing a widely applied method33 and using default parameters
unless otherwise stated. Criteria used by the Psychiatric Ge-
nomics Consortium31 were applied to select common single-
nucleotide variants (minor allele frequency, >0.10) of high-
quality (imputation score, >0.9) in relative linkage equilibrium
(r2 <0.2, 500-kilobyte window) that were present in all 3
samples. We excluded the extended major histocompatibil-
ity complex region (25-34 megabytes) given its complex link-
age disequilibrium structure. The PRSs for schizophrenia were
calculated for each study participant using summary statis-
tics from the largest available genome-wide association study34
after excluding the samples included in this study (summary
statistics derived specifically for the purposes of this study by
the Psychiatric Genomics Consortium Schizophrenia Work-
ing Group). Scores were also calculated using the largest avail-
able genome-wide association study for bipolar disorder,35 ma-
jor depression,36 autism spectrum disorder,37 attention-deficit/
hyperactivity disorder (ADHD),38 and intelligence.16 The first
5 genetic principal components were included as covariates
when generating each PRS. We selected the PRSs based on
single-nucleotide variants associated with a threshold of P ≤
.05 in the genome-wide association study sample for the pri-
mary analysis given that single-nucleotide variant inclusion
at this threshold gives the best prediction of schizophrenia,31
but as a secondary sensitivity test, we also looked across a range
of P value thresholds: 5 × 10−8, 1 × 10−7, 1 × 10−6, 1 × 10−5, 1 ×
10−4, 0.001, 0.05, 0.1, 0.2, 0.5, and 1.0.
Statistical Analysis
A confirmatory factor analysis (CFA) framework was used to es-
timate phenotype-derived dimension scores. First, CFA of symp-
tom and cognition measures was conducted on the Cardif-
fCOGS sample because CardiffCOGS had comprehensive ratings
for cognition and other symptoms not measured in the other
samples. Next, we fitted a multiple-group CFA model solely of
symptom ratings that were available across all 3 samples.
The lavaan package39 for R was used to identify all CFA
models. A series of prespecified models were examined in the
CardiffCOGS sample (detailed in eTable 2 in the Supplement)
using empirically derived and validated measurement mod-
els from previous publications.5,14 The Scale for the Assess-
ment of Positive Symptoms and Scale for the Assessment of
Negative Symptoms measures were global scores of symp-
tom categories, with the exception of inappropriate affect, and
were included on an ordinal (0-5) scale in the CFA models. All
MATRICS Consensus Cognitive Battery domain scores were
included on a continuous scale. Otherwise, we used default
parameters of the lavaan package, including fixing the first
indicator variable to 1, automatically adding residual vari-
ances, and allowing latent variables to be correlated.
The model that was considered to have the best fit was
selected for further analyses. Model fit was guided by both theo-
retical knowledge and standard interpretations of goodness-of-
fit indices,40,41 including (1) the standardized root mean square
residual (<0.08), (2) the root mean square error of approxima-
tion (<0.06), and (3) the comparative fit index (>0.95). eAppen-
dix 2 in the Supplement provides further details of goodness-
of-fit indices. Phenotype dimension scores were calculated for
each study participant from the CFA model.
Polygenic risk scores and phenotype dimension scores were
standardized before analysis. Each phenotype dimension (con-
sidered the dependent variable) was regressed on the schizo-
phrenia PRS using linear regression and including sex, age at in-
terview, and the first 5 genetic principal components as
covariates. For the multisample analysis, β values were meta-
analyzed using the R package meta,42 with a fixed-effect model
weighted by the SE. To control for multiple testing, a Bonfer-
roni correction was applied for the number of phenotype di-
mensions tested. In secondary analyses, we also tested the as-
sociation of PRSs for bipolar disorder, depression, ADHD, autism
spectrum disorder, and intelligence with each phenotype di-
mension. A Bonferroni correction was applied for testing 5 dis-
order PRSs multiplied by the number of phenotype dimen-
sions. In CardiffCOGS, we also tested the correlation of estimated
premorbid IQ with the derived cognitive dimension via Pear-
son correlation and assessed the association between premor-
bid IQ and schizophrenia PRS via linear regression.
Results
A total of 1220 individuals were included in the study; 817 were
men (67.0%), 403 were women (33.0%), and the mean (SD) age
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at study interview was 43.10 (12.74) years. eTable 1 in the
Supplement provides demographic information specific to each
sample.
The CFA models fitted in the CardiffCOGS sample are
detailed in eTable 2 in the Supplement. The optimal model
had 5 phenotypic dimensions relating to positive symp-
toms, negative symptoms of diminished expressivity, nega-
tive symptoms of motivation and pleasure, disorganized
symptoms, and cognitive ability. Figure 1 details the factor
loadings of contributing phenotypes from the optimal
model, which fitted the data well at the global level: com-
parative fit index, 0.99; root mean square error of approxi-
mation, 0.04; 95% CI, 0.03-0.05; and standardized root
mean square residual, 0.05.
A 3-factor CFA model was fitted across all 3 samples for
positive symptoms, negative symptoms of diminished expres-
sivity, and disorganized symptoms. The 3-factor model was a
good fit for the data in each sample; therefore no further post
hoc modifications to the model were made (eFigure 1 in the
Supplement details factor loadings and fit measures). The CFA
dimension scores derived from the 5-factor and 3-factor mod-
els were highly correlated (0.92-0.98).
Genetic Liability
Table 1 and Figure 2 detail the associations between schizo-
phrenia PRS and the phenotype dimensions from the Cardif-
fCOGS 5-factor model. Schizophrenia PRS was significantly
associated with higher scores on the disorganized dimension
(β = 0.14; 95% CI, 0.07-0.22; P = 2.80 × 10−4) and lower cur-
rent cognitive ability (β= −0.11; 95% CI, −0.19 to −0.04; P = 1.63
× 10−3). The dimension of negative symptoms of diminished
expressivity was associated at P < .05 (β = 0.09; 95% CI, 0.02-
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Structure of 5-factor phenotype
dimensions derived by confirmatory
factor analysis (CFA) in the
CardiffCOGS sample. Boxes on the
right detail contributing phenotypes,
and circles represent latent factors
created by CFA. Solid lines represent
standardized factor loadings, and
curved lines represent the correlation
among phenotype dimensions.
BVMT indicates Brief Visuospatial
Memory Test–Revised;
CPT, Continuous Performance Test:
Identical Pairs; negative EXP,
negative symptoms of diminished
expressivity; HVLT, Hopkins Verbal
Learning Test; and negative MAP,
negative symptoms of diminished
motivation and pleasure.
Table 1. Association of Schizophrenia PRS and Phenotype Dimensions From 5-Factor Model
Phenotype dimension
CardiffCOGS (n = 662)
β (95% CI) SE R2 P valuea
Positive −0.03 (−0.11 to 0.05) 0.039 <0.001 .422
Negative
Diminished expressivity 0.09 (0.02 to 0.17) 0.039 0.007 .015
Motivation and pleasure 0.04 (−0.03 to 0.12) 0.039 <0.001 .258
Disorganized 0.14 (0.07 to 0.22) 0.039 0.019 2.80 × 10−4
Cognition −0.11 (−0.19 to −0.04) 0.036 0.012 1.63 × 10−3
Abbreviation: PRS, polygenic risk
score.
a Determined with regression
analyses.
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0.17; P = .015) but did not survive a Bonferroni correction for
the 5 dimensions tested (P < .01). These associations were con-
sistent across different P thresholds for single-nucleotide vari-
ant inclusion in the PRS (eTable 3 in the Supplement), but as
expected, the optimal threshold was our primary P threshold
of .05, which typically captures maximum heritability. To as-
sess whether the phenotypic dimensions were indepen-
dently associated with the PRS, we regressed the schizophre-
nia PRS against all phenotype dimensions simultaneously. In
this model, the dimensions relating to disorganized symp-
toms and current cognitive ability remained significantly as-
sociated with schizophrenia PRS, whereas the dimension of
negative symptoms of diminished expressivity did not
(eTable 4 in the Supplement).
To confirm the findings applied to raw symptoms scores,
we tested the association between schizophrenia PRS and
summed raw phenotype scores used to create the symptom
dimensions and the MATRICS Consensus Cognitive Battery
composite score for cognition, as opposed to the latent fac-
tors defined by CFA, and found that schizophrenia PRS was
associated only with disorganized symptoms (β = 0.24; 95%
CI, 0.11-0.37; P = 2.12 × 10−4) and current cognitive ability
(β = −0.13; 95% CI, −0.23 to −0.04; P = 4.63 × 10−3) (eFig-
ure 2, eTable 5 in the Supplement). Schizophrenia PRS was
associated with both of the variables used to create the disor-
ganized dimension when entered into the same model simul-
taneously: positive formal thought disorder (β = 0.10; 95% CI,
0.02-0.18; P = .01) and inappropriate affect (β = 0.08; 95% CI,
0.01-0.16; P = .04). Schizophrenia PRS remained associated
with the disorganized and cognitive dimensions when con-
trolling for potential confounders of age at the onset of psy-
chosis and treatment resistance to antipsychotics (eTable 6 in
the Supplement).
In a meta-analysis of the multisample 3-factor model
(Table 2, Figure 2B), schizophrenia PRS was significantly
associated with the disorganized dimension (β = 0.10; 95%
CI, 0.05-0.15; P = 2.80 × 10−4) after correction for multiple
testing, but not with the dimensions relating to negative
symptoms of diminished expressivity (β = 0.06; 95% CI,
0.00-0.12; P = .038) or positive symptoms (β = −0.02; 95%
CI, −0.06 to 0.02; P = .367). Tests for heterogeneity (Coch-
ran Q and I2) indicated that the studies in the meta-analysis
had consistent outcomes for all phenotype dimensions
studied.
Figure 3 and eTable 7 in the Supplement detail the asso-
ciations between the 5-factor phenotype dimensions in Car-
diffCOGS and PRSs for bipolar disorder, depression, autism,
ADHD, and intelligence at the threshold P ≤ .05. The only
association that survived a Bonferroni correction for the num-
ber of tests conducted (n = 25; P < .002) was between the in-
telligence PRS and current cognitive ability (β = 0.23; 95% CI,
0.16 to 0.30; P = 1.52 × 10−10).
In meta-analysis for the 3-factor model, none of the PRSs
for bipolar disorder, depression, autism, ADHD, or intelli-
Figure 2. Association of Schizophrenia Polygenic Risk Score and Phenotype Dimensions
–0.2 0.2 0.30–0.1 0.1
β (95% CI)
Dimensional structure β (95% CI)
Positive –0.03 (–0.11 to 0.05)
Negative: diminished expressivity 0.09 (0.02 to 0.17)
Negative: motivation and pleasure 0.04 (–0.03 to 0.12)
Disorganized 0.14 (0.07 to 0.22)
5-Factor modelA
–0.3 0.3 0.4 0.50 0.2–0.1 0.1–0.2
β (95% CI)
Dimensional structure β (95% CI)
Positive
CardiffCOGS –0.03 (–0.11 to 0.06)
Cardiff F-series –0.02 (–0.07 to 0.03)
Cardiff affected-Sib –0.01 (–0.24 to 0.22)
Meta-analysis –0.02 (–0.06 to 0.02)
Negative: diminished expressivity
CardiffCOGS 0.06 (–0.01 to 0.13)
Cardiff F-series 0.06 (–0.06 to 0.17)
Cardiff affected-Sib 0.10 (–0.15 to 0.35)
Meta-analysis 0.06 (0.00 to 0.12)
Disorganized
CardiffCOGS 0.10 (0.04 to 0.17)
Cardiff F-series 0.08 (–0.04 to 0.20)
Cardiff affected-Sib 0.14 (–0.15 to 0.43)
Meta-analysis 0.10 (0.05 to 0.15)
3-Factor modelB
Cognition –0.11 (–0.19 to –0.04)
Association of schizophrenia
polygenic risk scores with phenotype
dimensions. A, The association (β)
with phenotypes derived in the
5-factor model in the CardiffCOGS
sample. B, The association (β) with
phenotypes derived in the 3-factor
model for each of the 3 contributing
samples and combined
meta-analysis. All error bars
represent the 95% CI of the β value.
Dotted line represents a null model
(values >0 indicate increased risk and
values <0 indicate reduced risk).
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gence were significantly associated with any of the symptom
dimensions after correction for multiple testing (eTable 8 in
the Supplement).
The intelligence PRS was strongly associated with premor-
bid IQ as measured by the National Adult Reading Test
(β = 0.33; 95% CI, 0.26-0.41; P = 4.76 × 10−17), whereas the
schizophrenia PRS was not (β = −0.04; 95% CI, −0.12 to 0.04;
P = .323). Premorbid IQ and the current cognitive ability
dimension had a Pearson correlation of 0.50. We added pre-
morbid IQ as a covariate in the regressions of the current cog-
nitive ability dimension, as defined in the 5-factor CFA model,
on the PRSs for schizophrenia and intelligence—a method that
has been demonstrated to be preferable to the creation of
change scores.43 The association between current cognitive
ability and schizophrenia PRS remained significant (β = −0.08;
95% CI, −0.14 to −0.02; P = 8.50 × 10−3), whereas the compari-
son with intelligence PRS did not (β = 0.06; 95% CI, −0.01-
0.12; P = .08).
Discussion
In this study, we found evidence that higher levels of disor-
ganized symptoms and lower levels of current cognitive abil-
ity were significantly associated with schizophrenia PRS, sug-
gesting that these phenotypes are markers of increased genetic
liability to schizophrenia. We also found that current cogni-
tive performance in schizophrenia reflects genetic liabilities
to both schizophrenia and intelligence.
Our first notable finding relates to the association be-
tween schizophrenia PRS and disorganized dimension scores
in individuals with schizophrenia based on lifetime worst rat-
ings; we found a significant association in the 5-factor model
derived in our largest sample and in a meta-analysis of a 3-fac-
tor model across 3 samples. This finding is consistent with a
twin study that found that the disorganized symptom dimen-
sion was a marker of genetic loading for psychotic disorders.2
Table 2. Meta-analysis of Schizophrenia PRS and Phenotype Dimensions From Multisample 3-Factor Model
Symptom
dimension
CardiffCOGS (n = 697)a Cardiff F-series (n = 383) Cardiff affected-sib (n = 140) Meta-analysis (n = 1220)
β (95% CI) SE P value β (95% CI) SE
P
value β (95% CI) SE
P





















0.035 .098 0.06 (−0.06
to 0.17)
0.057 .321 0.10 (−0.15
to 0.35)





0.032 1.14×10−3 0.08 (−0.04
to 0.20)
0.059 .179 0.14 (−0.15
to 0.43)
0.147 .342 0.10 (0.05
to 0.15)
2.80×10−4 0.20 .903
Abbreviation: PRS, polygenic risk score.
a The sample size for CardiffCOGS is larger than in the 5-factor model owing to
the inclusion of 35 individuals who were missing data for either cognitive
ability or negative symptoms of motivation and pleasure and thus excluded
from the 5-factor model.

























Association of polygenic risk scores (PRSs) for schizophrenia, attention-deficit/
hyperactivity disorder (ADHD), autism spectrum disorder, bipolar disorder,
depression, and intelligence with phenotype dimensions derived from the
5-factor model in CardiffCOGS. Error bars represent the 95% CI of the β value.
Dotted line represents a null model (values >0 indicate increased risk and values
<0 indicate reduced risk).
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We noted little evidence that the disorganized dimension was
significantly associated with genetic liability to other neuro-
psychiatric disorders or intelligence, suggesting some speci-
ficity with schizophrenia genetic liability.
Previous studies assessing the relationships between
schizophrenia PRS and symptom dimensions in schizophre-
nia have reported associations with a combined negative/
disorganized dimension.9,10 Follow-up analyses in one of these
studies of raw symptom scores found that this signal ap-
peared to be influenced by the disorganized rather than the
negative symptom scores.10 Our study clarifies the associa-
tions between schizophrenia PRS and symptom dimensions
by including distinct disorganized and negative dimensions in
the primary analysis. We found that, although schizophrenia
PRS was nominally associated with the dimension relating to
negative symptoms of diminished expressivity in our largest
sample, this association attenuated when included in a model
with the disorganized dimension and was not associated in the
meta-analysis of the 3-factor model or with the raw pheno-
types. Thus, our findings suggest that the association with ge-
netic liability to schizophrenia is principally associated with
disorganized rather than negative symptoms. These findings
support the importance of developing better assessments and
capturing subjective and observed data for disorganized symp-
toms in schizophrenia research, which may have particular rel-
evance for clinical studies into basic symptoms44 and genetic
high risk.
The lack of association between genetic liability for schizo-
phrenia and positive symptoms is consistent with previous
studies in individuals with schizophrenia.2,9,10,13 Our study ex-
tends these findings to show that, in people with schizophre-
nia, there is no association between positive symptoms and
genetic liability for bipolar disorder, depression, ADHD, au-
tism, or intelligence.
The second key finding from this study concerns the as-
sociations between schizophrenia PRS, intelligence PRS, and
current cognitive ability. Although both sets of PRSs were as-
sociated with current cognitive ability, the intelligence PRS, but
not the schizophrenia PRS, was associated with premorbid IQ
as estimated by the National Adult Reading Test. Moreover,
when adding premorbid IQ as a covariate, the association be-
tween current cognitive ability and schizophrenia PRS re-
mained significant, but the association with intelligence PRS
did not. These results suggest that current cognitive ability in
individuals with schizophrenia is partly a function of premor-
bid IQ, influenced by genetic variants that contribute to varia-
tion in intelligence in the general population and addition-
ally influenced by schizophrenia risk alleles. The latter could
affect cognitive ability via processes intrinsic to schizophre-
nia pathophysiologic factors and/or via consequences of hav-
ing schizophrenia, such as medication effects or social isola-
tion. It is of interest that a recent study of 22q11.2 deletion
syndrome also found evidence of an association between de-
cline in intelligence and schizophrenia PRS.45 Another possi-
bility is that schizophrenia PRS predominantly influences fluid
intelligence (primary component of the MATRICS Consensus
Cognitive Battery) as opposed to crystallized intelligence (pri-
mary component of the National Adult Reading Test), which
may be more related to intelligence PRS.46 The genetic basis
of cognitive impairment in schizophrenia is an important area
for future research given the association between cognitive im-
pairment and poor functional outcome in schizophrenia.47
Studies investigating the association between schizophrenia
PRS and cognitive ability in patients with schizophrenia have
reported inconsistent findings,4,17 which may be owing to dif-
ferences in the duration between schizophrenia onset and cog-
nitive assessment and the aspects of cognition measured.48
The phenotypic correlation between the disorganized and
cognitive ability dimensions in our study was low (−0.12), con-
sistent with previous studies,49 and in the model including all
dimensions, schizophrenia PRS was significantly associated
with both the disorganized and cognitive ability dimensions.
These findings suggest that disorganized symptoms and cur-
rent cognitive ability in patients with schizophrenia are in-
dependent markers of genetic liability to schizophrenia. In
addition to disorganized symptoms and cognitive ability being
influenced by common schizophrenia genetic risk factors, these
and the other phenotypes assessed might be influenced by rarer
schizophrenia genetic risk factors, genetic factors indepen-
dent of schizophrenia liability, and a range of environmental
factors.1
Strengths and Limitations
A key strength of this study is the use of 3 independent samples,
each with well-characterized symptom data derived from both
interview and clinical case records focusing on lifetime symp-
toms. The symptom dimensions were identified from the Scale
for the Assessment of Positive Symptoms and Scale for the As-
sessment of Negative Symptoms in all 3 samples, thus allow-
ing for relatively high consistency of symptom dimension mea-
sures. The study included cognitive ability as well as symptom
dimensions as distinct phenotypes and optimized pheno-
typic structure using confirmatory factor analysis.
However, the study findings should be interpreted in the
context of several limitations. The results presented in this
study are limited by the fact that cognitive data were not avail-
able in 2 of the samples, and thus these results require repli-
cation in other samples that have dimensional phenotypes in-
cluding disorganized symptoms and cognitive measures. The
lifetime symptom scores were based in part on retrospective
reports during interviews, but their use in conjunction with
contemporaneous clinical records will have increased the ac-
curacy of the phenotypic measures. In addition, our analyses
consisted of individuals of White European ancestry because
the sample contained too few participants of non-European
ancestry to analyze thoroughly. Thus, further studies are re-
quired to establish the generalizability of these findings to all
people with schizophrenia.
Conclusions
The results of this study suggest that variation in disorga-
nized symptoms and cognitive ability in schizophrenia are
independent markers of the extent to which individuals carry
common genetic risk variants for schizophrenia. Moreover, cog-
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nitive performance in schizophrenia reflects genetic liabili-
ties to both schizophrenia and intelligence. Further investi-
gation of the genetic basis of these phenotypes and the
underlying mechanisms may have potential to improve diag-
nosis, prognosis, and development of treatments for aspects
of schizophrenia currently associated with poor outcomes.
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